Skip to main navigation

Press Releases

Year

Dec 09, 2024

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Dec 02, 2024

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

Nov 12, 2024

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Nov 08, 2024

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Nov 05, 2024

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations

Oct 28, 2024

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Oct 16, 2024

Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress

Sep 19, 2024

Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

Aug 27, 2024

Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024

Aug 08, 2024

Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 30